On August 24, Hong Kong stocks saw a deep correction, with the healthcare sector, which had been a recent hotspot, also moving lower. The Hong Kong Stock Connect innovative drug segment opened higher but trended downward, with Livzon Pharmaceutical Group leading the decline at 15.73%, while heavyweight names BeiGene and Innovent Biologics fell over 2.8%. In contrast, CSPC Pharmaceutical Group bucked the trend, rising 2.23%. The Hua Bao Hong Kong Stock Connect Innovative Drug ETF (520880), which focuses entirely on innovative drug R&D targets, posted a second consecutive daily loss, closing below its 50-day moving average after a volatile session with an intraday range of 3.44% and turnover of 318 million yuan.

The broader Hong Kong-listed healthcare segment saw an even steeper correction. Xin Tai Medical dropped 9.2% following its earnings release, while CXO names collectively weakened: WuXi Biologics pulled back 4.71%, WuXi AppTec fell 3.94%, AI-driven drug developer GenScript Biotech slid 5.28%, and internet healthcare leader JD Health lost 3.47%. The Hua Bao Hong Kong Stock Connect Healthcare ETF (159137), which holds over half its positions in CXO stocks, traded in deep water, losing both its 5-day and 10-day moving averages. Notably, this ETF had posted five consecutive weekly gains through last week, fueled by CXO strength.

So, what is driving the broad selloff in Hong Kong healthcare stocks? On one hand, the overall Hong Kong market declined, dampening sentiment. The Hang Seng Index closed down 1.89% on the day, while the Hang Seng Tech Index tumbled 3.61%. On the news front, Alibaba announced on August 23 a placement to raise HK$80 billion. As a heavyweight stock in the Hong Kong market, this large discounted share sale could create a short-term 'liquidity drain' effect and valuation pressure, unsettling market sentiment. On the other hand, with the interim earnings season underway, some healthcare stock movements may be tied to earnings results. Livzon Pharmaceutical Group, which fell sharply today, reported on August 22 that its net profit attributable to shareholders stood at 932 million yuan, down 27.23% year-on-year. Similarly, Xin Tai Medical disclosed on the same day that its first-half net profit attributable to shareholders was 146 million yuan, a 19.49% decline year-on-year.

Additionally, Hong Kong healthcare stocks had seen a significant recovery since August, accumulating substantial unrealized gains. Shifts in short-term market preferences could trigger profit-taking and selling pressure. However, short-term volatility does not change the underlying investment thesis for healthcare. The innovative drug industry's upward cycle remains intact, and pullbacks in the sector may warrant increased attention. Huayuan Securities stated: 'Looking to Q4, we hold strong confidence in the healthcare sector. Innovative drugs are likely to see a trend where individual stocks drive the broader sector, and we are optimistic about the subsequent share price performance of certain core assets.' On the industry chain front, overall sector activity remains high, with CDMO and early-stage research segments showing strong earnings visibility. Some core assets may experience a 'Davis Double Play.'

For full-chain exposure to innovative drugs, two T+0 tools are worth watching. The Hua Bao Hong Kong Stock Connect Innovative Drug ETF (520880) passively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, with 100% allocation to innovative drug R&D companies and 70% of positions in R&D leaders. Its off-exchange feeder fund is 025221. The Hua Bao Hong Kong Stock Connect Healthcare ETF (159137) passively tracks the Hong Kong Stock Connect Healthcare Thematic Index, heavily weighted toward the innovative drug supply chain, with 50% in CXO and 20% in innovative drugs, of which WuXi-related companies account for over 38%. Its off-exchange feeder fund is 026922.

Data is sourced from public information from the Shanghai, Shenzhen, and Hong Kong exchanges, CSI Index, and Hang Seng Index. Weight data is as of August 21, 2026, per Huayuan Securities' August 23, 2026 report 'Healthcare Industry Weekly: Interim Results Rolling Out, Focus on Traditional Big Pharma Opportunities.' Note: ETFs do not charge sales service fees. When subscribing or redeeming fund shares, agents may charge commissions up to 0.5%, including fees levied by securities exchanges and registration institutions. Fund rates are detailed in each fund's legal documents. Risk warning: The index constituents mentioned are for illustration only and do not constitute investment advice or represent the holdings or trading activities of any fund under the manager. Weightings of mentioned stocks in the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index: BeiGene 12.06%, Innovent Biologics 11.60%, CSPC Pharmaceutical Group 10.16%, and Livzon Pharmaceutical Group 0.51%. Weightings in the Hong Kong Stock Connect Healthcare Thematic Index: WuXi Biologics 18.70%, WuXi AppTec 15.25%, GenScript Biotech 7.90%, JD Health 7.45%, and Xin Tai Medical only 0.23%. The fund manager assesses the risk level of the Hua Bao Hong Kong Stock Connect Healthcare ETF and the Hua Bao Hong Kong Stock Connect Innovative Drug ETF as R4 (medium-high risk), suitable for active (C4) and above investors. Any information in this article (including but not limited to stocks, comments, forecasts, charts, indicators, theories, or any form of expression) is for reference only. Investors are solely responsible for their own investment decisions. Any views, analyses, or forecasts herein do not constitute investment advice to readers and do not bear responsibility for any direct or indirect losses arising from the use of this content. Past performance of funds managed by the manager does not guarantee future performance. Fund investment carries risks.

MACD golden cross signal forming, these stocks are trending well!